Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

VERA

Vera Therapeutics Inc

Feb 13 • 04:00PM ET

42.22

-0.02 -0.05 %

Healthcare • Biotechnology • USA • NASD

Peers: ARVN INCY ITCI ALXO BCRX RIGL LGND KURA CRVS AVIR

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-3.99	Insider Own	19.17%	Shs Outstand	63.89M	Perf Week	-2.94%
Market Cap	2.96B	Forward P/E	-	EPS next Y	-4.70	Insider Trans	-0.32%	Shs Float	56.63M	Perf Month	-12.79%
Enterprise Value	2.54B	PEG	-	EPS next Q	-1.28	Inst Own	85.88%	Short Float	14.29%	Perf Quarter	35.84%
Income	-251.94M	P/S	-	EPS this Y	-64.80%	Inst Trans	-1.77%	Short Ratio	5.97	Perf Half Y	98.50%
Sales	0.00M	P/B	6.76	EPS next Y	-3.64%	ROA	-56.87%	Short Interest	8.09M	Perf YTD	-16.63%
Book/sh	6.24	P/C	5.95	EPS next 5Y	2.47%	ROE	-73.25%	52W High	56.05 -24.67%	Perf Year	23.52%
Cash/sh	7.10	P/FCF	-	EPS past 3/5Y	-21.52% 4.49%	ROIC	-52.97%	52W Low	18.53 127.85%	Perf 3Y	462.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.75% 5.23%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-53.44%	Oper. Margin	-	ATR (14)	2.36	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.09	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.99	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	12.09	EPS Q/Q	-48.06%	SMA20	-5.45%	Beta	1.17	Target Price	75.15
Payout	-	Debt/Eq	0.19	Sales Q/Q	-	SMA50	-9.99%	Rel Volume	1.18	Prev Close	42.24
Employees	112	LT Debt/Eq	0.19	Earnings	Nov 05 BMO	SMA200	38.91%	Avg Volume	1.36M	Price	42.22
IPO	May 14, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.40% -	Trades		Volume	1,603,312	Change	-0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Initiated	BofA Securities	Buy	$48
Aug-04-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-05-25	Resumed	H.C. Wainwright	Buy	$75
Feb-04-25	Initiated	Wolfe Research	Outperform	$49
Jan-28-25	Initiated	Goldman	Buy	$58
Nov-21-24	Initiated	Wells Fargo	Overweight	$70
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Show Previous Ratings

Feb-07-26 11:35AM	Vera Therapeutics, Inc. (VERA): A Bull Case Theory (Insider Monkey)
Feb-06-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.23%
Jan-30-26 12:24AM	Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential? (Insider Monkey)
Jan-28-26 07:30AM	Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer (GlobeNewswire)
Jan-23-26 11:09AM	Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns (Insider Monkey)
11:35AM	Loading…
Jan-15-26 11:35AM	Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept (Insider Monkey)
Jan-14-26 09:55AM	Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High? (Zacks)
Jan-09-26 01:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-26 07:30AM	Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-26 07:41PM	Why Vera Therapeutics Stock Zoomed Higher Today (Motley Fool)
07:30AM	Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy (GlobeNewswire)
Dec-09-25 08:57PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire)
Dec-08-25 04:01PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Dec-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.37%
Dec-02-25 07:42PM	Why Vera Therapeutics Stock Rocked the Market on Tuesday (Motley Fool) +12.88% +10.77%
01:09PM	Loading…
01:09PM	Stock Market Today: MongoDB, Boeing, and Intel Define Tuesday Trade As Market Bounces Back From Post-Thanksgiving Blues (TheStreet)
Nov-26-25 07:45PM	Why Vera Therapeutics Stock Crushed it Today (Motley Fool) +13.25%
04:05PM	Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors (GlobeNewswire)
Nov-24-25 07:25AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-18-25 02:20PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-16-25 10:14PM	H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth (Insider Monkey)
Nov-14-25 09:01AM	Yale University's Strategic Investment in Vera Therapeutics Inc: A 32.26% Portfolio Stake (GuruFocus.com)
Nov-10-25 07:29AM	Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) +14.72%
Nov-07-25 06:27PM	Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy (GlobeNewswire)
04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:51AM	Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine (GlobeNewswire)
Nov-05-25 07:29AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 08:00AM	Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET (GlobeNewswire)
Oct-20-25 11:08PM	BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating (Insider Monkey)
Oct-17-25 09:12AM	Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 (GlobeNewswire)
04:05PM	Loading…
Oct-10-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.46%
Aug-26-25 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) +5.62%
Aug-08-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 07:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:35AM	Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 07:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 08:07AM	Millions in Insider Buying Point to These 2 Stocks Heres What It Could Signal (TipRanks)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:02AM	Biotech Stock Vera Is Slumping After Monster Gain (Barrons.com) -25.89%
07:49AM	Vera Therapeutics stock sinks following competitors successful trial (Investing.com)
Jun-04-25 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-25 06:30AM	Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans (GlobeNewswire)
02:22AM	Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 06:30AM	Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy (GlobeNewswire) +67.49%
04:51AM	Vera drug scores in closely watched study in rare kidney disease (BioPharma Dive)
May-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-25 08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -13.79%
Apr-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.76%
02:51PM	Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch (Benzinga)
Apr-03-25 08:00AM	Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN (GlobeNewswire)
Mar-11-25 04:28PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:00AM	Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.91%
Feb-26-25 08:25AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.66%
Jan-14-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 07:00AM	Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor (GlobeNewswire) -6.08%
Jan-07-25 04:05PM	Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 06:29PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-18-24 08:00AM	Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer (GlobeNewswire)
Nov-11-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:55AM	Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
08:00AM	Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study (GlobeNewswire)
Nov-08-24 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 08:21PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire) -9.23% -5.42%
09:25AM	Vera Therapeutics price target raised to $64 from $56 at Guggenheim (TipRanks)
Oct-28-24 05:43PM	Vera Therapeutics Breaks Out On Promising Results For Kidney Drug (Investor's Business Daily) +15.21%
05:37PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
10:33AM	Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years (Benzinga)
10:13AM	Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug (Investor's Business Daily)
Oct-26-24 07:30PM	Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Oct-04-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-24 06:30AM	Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
06:30AM	Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases (GlobeNewswire)
Sep-26-24 03:31PM	Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-16-24 08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 (GlobeNewswire) +6.90%
Sep-12-24 08:00AM	Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN (GlobeNewswire) -5.08%
Sep-10-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-03-24 08:27AM	Adobe Stock Added to JP Morgan Focus List. Heres Why. (Barrons.com)
08:27AM	Adobe and 2 More Stocks Added to JP Morgan Focus List. Heres Why. (Barrons.com)
07:49AM	Load Up on Adobe and These 2 Stocks This September, J.P. Morgan Says (Barrons.com)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Vera Therapeutics to Participate at September Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 04:30PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 08:00AM	Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer (GlobeNewswire)
Jun-11-24 04:01PM	Vera Therapeutics Appoints Christy J. Oliger to Board of Directors (GlobeNewswire)
Jun-07-24 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 08:00AM	Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) (GlobeNewswire)
May-25-24 09:40AM	Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress (GlobeNewswire)
May-17-24 04:27PM	Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing (MT Newswires)
May-10-24 05:38AM	Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating (MT Newswires)
May-09-24 01:53PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -5.81%
08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 17 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Sale	50.08	10,000	500,767	22,500	Dec 17 04:05 PM
ENRIGHT PATRICK G	Director	Dec 11 '25	Buy	42.50	5,882	249,985	5,882	Dec 15 08:07 PM
WILLIAM TURNER	Officer	Dec 15 '25	Proposed Sale	49.80	10,000	498,000		Dec 15 04:17 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 10 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Sale	45.31	10,000	453,053	22,500	Dec 10 04:05 PM
WILLIAM TURNER	Officer	Dec 08 '25	Proposed Sale	44.90	10,000	449,000		Dec 08 04:41 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 04 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Sale	40.00	10,000	400,000	22,500	Dec 04 04:05 PM
WILLIAM TURNER	Officer	Dec 03 '25	Proposed Sale	37.25	10,000	372,500		Dec 03 04:31 PM
Carter Jason S	Chief Legal Officer	Nov 21 '25	Sale	27.82	3,864	107,498	49,136	Nov 25 04:05 PM
Carter Jason S	Officer	Nov 21 '25	Proposed Sale	27.87	3,864	107,690		Nov 24 09:22 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 13 '25	Option Exercise	3.94	10,000	39,396	57,839	Nov 13 08:57 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 11 '25	Sale	29.06	15,000	435,874	47,839	Nov 13 08:57 PM
ENRIGHT PATRICK G	Director	Jun 23 '25	Buy	20.87	209,393	4,369,676	3,569,522	Jun 25 08:07 PM
ENRIGHT PATRICK G	Director	Jun 24 '25	Buy	22.35	40,607	907,635	3,596,593	Jun 25 08:07 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 21 '25	Sale	27.89	10,613	296,032	213,740	Feb 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 26 '25	Sale	27.65	9,075	250,882	204,665	Feb 27 04:05 PM
MARSHALL FORDYCE	Director	Feb 26 '25	Proposed Sale	27.10	9,075	245,932		Feb 26 04:21 PM

Open in Screener

VTGN

Vistagen Therapeutics Inc

Feb 13 • 04:00PM ET

0.5056

-0.0394 -7.23 %

Healthcare • Biotechnology • USA • NASD

VTGN Vistagen Therapeutics Inc daily Stock Chart

Peers: BIIB NBIX ALNY ONC ACAD CORT EDIT FATE AUPH MDGL

| Held by: VTI VXF PSIL IWC DFAS DCOR

Index	-	P/E	-	EPS (ttm)	-1.58	Insider Own	14.79%	Shs Outstand	39.62M	Perf Week	-10.23%
Market Cap	20.03M	Forward P/E	-	EPS next Y	-1.14	Insider Trans	0.00%	Shs Float	33.76M	Perf Month	-27.93%
Enterprise Value	-40.31M	PEG	-	EPS next Q	-0.34	Inst Own	43.40%	Short Float	6.03%	Perf Quarter	-87.58%
Income	-47.30M	P/S	28.61	EPS this Y	-6.71%	Inst Trans	13.79%	Short Ratio	0.73	Perf Half Y	-82.89%
Sales	0.70M	P/B	0.39	EPS next Y	35.80%	ROA	-42.35%	Short Interest	2.04M	Perf YTD	-23.61%
Book/sh	1.29	P/C	0.32	EPS next 5Y	15.53%	ROE	-46.28%	52W High	5.14 -90.16%	Perf Year	-82.26%
Cash/sh	1.56	P/FCF	-	EPS past 3/5Y	39.12% 35.63%	ROIC	-92.12%	52W Low	0.50 0.56%	Perf 3Y	-92.64%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-24.04% -	Gross Margin	11.86%	Volatility	11.17% 7.83%	Perf 5Y	-99.12%
Dividend TTM	-	EV/Sales	-57.59	EPS Y/Y TTM	54.91%	Oper. Margin	-7566.52%	ATR (14)	0.08	Perf 10Y	-99.79%
Dividend Ex-Date	-	Quick Ratio	4.67	Sales Y/Y TTM	-33.00%	Profit Margin	-6774.22%	RSI (14)	27.70	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.67	EPS Q/Q	-5.77%	SMA20	-13.09%	Beta	0.30	Target Price	0.97
Payout	-	Debt/Eq	0.03	Sales Q/Q	65.57%	SMA50	-63.14%	Rel Volume	1.19	Prev Close	0.55
Employees	57	LT Debt/Eq	0.01	Earnings	Feb 12 AMC	SMA200	-81.20%	Avg Volume	2.78M	Price	0.51
IPO	Jun 21, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.58% -16.85%	Trades		Volume	3,300,152	Change	-7.23%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-25	Downgrade	William Blair	Outperform → Mkt Perform
Dec-17-25	Downgrade	Stifel	Buy → Hold	$1
Dec-17-25	Downgrade	Maxim Group	Buy → Hold
Dec-17-25	Downgrade	Jefferies	Buy → Hold	$0.90
Dec-07-23	Upgrade	Jefferies	Hold → Buy	$15
Aug-07-23	Upgrade	Maxim Group	Hold → Buy	$30
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	Jefferies	Buy → Hold
May-20-21	Initiated	Robert W. Baird	Outperform	$9
Feb-18-21	Initiated	Jefferies	Buy	$6
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy	$6
Feb-08-18	Reiterated	Chardan Capital Markets	Buy	$30 → $22
Mar-28-17	Initiated	Maxim Group	Buy	$4

Show Previous Ratings

Feb-13-26 08:30AM	VistaGen Therapeutics, Inc. Q3 2026 Earnings Call Summary (Moby) -7.23%
12:02AM	Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ... (GuruFocus.com)
Feb-12-26 05:45PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:30PM	Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update (Business Wire)
Feb-11-26 07:39AM	Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2026 Result (GuruFocus.com)
05:19AM	Loading…
Feb-05-26 05:19AM	Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN (PR Newswire)
Feb-04-26 08:30AM	Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026 (Business Wire)
Jan-29-26 04:27AM	Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN (PR Newswire) -7.60%
Jan-19-26 01:50AM	Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN (PR Newswire)
Dec-17-25 08:30AM	Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder (Business Wire) -80.25%
Dec-01-25 08:30AM	Vistagen Appoints Nick Tressler as Chief Financial Officer (Business Wire) -9.59%
Nov-26-25 08:30AM	Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting (Business Wire)
Nov-14-25 12:06AM	Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ... (GuruFocus.com)
Nov-13-25 05:55PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.63%
04:30PM	Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update (Business Wire)
08:45AM	Loading…
Nov-12-25 08:45AM	XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:31AM	What To Expect From Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings (GuruFocus.com)
Nov-10-25 08:30AM	Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025 (Business Wire)
Nov-05-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:30AM	Vistagen to Participate in Stifel Healthcare Conference 2025 (Business Wire)
Nov-03-25 08:30AM	Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder (Business Wire) +7.61%
Nov-02-25 05:05AM	Analysts Predict Up to 550% Rally for These 2 Strong Buy Penny Stocks (TipRanks)
Oct-30-25 08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.30%
Oct-29-25 05:20PM	Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:30AM	Vistagen Appoints Paul Edick to its Board of Directors (Business Wire)
Oct-28-25 05:23AM	Arcus Biosciences (RCUS) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
Oct-16-25 08:30AM	Vistagen to Present at The Menopause Society 2025 Annual Meeting (Business Wire)
Sep-26-25 02:30PM	Janus Henderson Just Took a 13.6% Stake in Vistagen. Should You Buy VTGN Stock Now? (Barchart)
Sep-09-25 08:30AM	Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (Business Wire)
Sep-02-25 03:51AM	Vistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety Trial (Insider Monkey) +5.39%
09:02AM	Loading…
Aug-08-25 09:02AM	Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ... (GuruFocus.com) +8.79%
Aug-07-25 07:20PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.08%
04:30PM	Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update (Business Wire)
Aug-06-25 06:15PM	Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Aug-05-25 10:00AM	Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-31-25 08:30AM	Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025 (Business Wire)
Jul-24-25 08:30AM	Vistagen to Present at the BTIG Virtual Biotechnology Conference (Business Wire)
Jul-15-25 08:30AM	Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership (Business Wire) -5.46%
Jul-02-25 10:03PM	Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay (Insider Monkey)
Jun-25-25 08:30AM	Vistagen Appoints Elissa Cote as Chief Corporate Development Officer (Business Wire)
Jun-18-25 03:01AM	Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com) -13.45%
Jun-17-25 04:30PM	Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update (Business Wire)
05:20AM	Results season slows to a dribble (MarketWatch)
04:11AM	Stock Market Today: Dow, S&P 500 and Nasdaq marked lower as Trump says to 'evacuate Tehran' with Fed decision, retail sales on tap (MarketWatch)
Jun-16-25 09:16AM	Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For (GuruFocus.com) +6.79%
Jun-12-25 08:30AM	Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025 (Business Wire)
Jun-02-25 08:30AM	Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year (Business Wire) -6.01%
May-28-25 08:30AM	Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York (Business Wire)
May-23-25 08:30AM	Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference (Business Wire)
May-15-25 09:15AM	Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-14-25 05:35PM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-13-25 05:15PM	Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-17-25 08:30AM	Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference (Business Wire)
Mar-19-25 08:30AM	Vistagen to Present at the 2025 Anxiety and Depression Association Conference (Business Wire)
Mar-04-25 08:30AM	Vistagen to Participate in Stifel 2025 Virtual CNS Forum (Business Wire) +6.43%
Feb-20-25 08:30AM	Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference (Business Wire)
Feb-14-25 02:22AM	Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com)
Feb-13-25 05:55PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:30PM	Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update (Business Wire)
Feb-12-25 07:51AM	Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result (GuruFocus.com)
Feb-06-25 08:30AM	Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 (Business Wire)
Feb-05-25 08:30AM	Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain (Business Wire)
Jan-15-25 05:16AM	Vistagen reports positive outcomes from Phase IIA cancer cachexia trial (Clinical Trials Arena)
Jan-14-25 08:30AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia (Business Wire)
Jan-10-25 08:30AM	Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder (Business Wire)
Nov-14-24 08:30AM	Vistagen to Present at the Stifel 2024 Healthcare Conference (Business Wire)
Nov-08-24 02:31AM	Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... (GuruFocus.com)
Nov-07-24 07:30PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update (Business Wire)
Nov-06-24 07:51AM	Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Nov-05-24 08:30AM	Vistagen to Present at the 2024 Neuroscience Education Institute Congress (Business Wire)
Nov-01-24 08:30AM	Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 (Business Wire)
Oct-11-24 12:00PM	VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know (Zacks)
Oct-09-24 06:20PM	Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com)
08:30AM	Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day (Business Wire)
Sep-24-24 04:52AM	Vistagen enrols first subject in Phase III trial of social anxiety disorder drug (Clinical Trials Arena)
Sep-23-24 08:30AM	Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder (Business Wire)
Sep-06-24 12:00PM	All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:30PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:21PM	Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update (Business Wire)
Aug-06-24 08:30AM	Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 (Business Wire)
Jul-26-24 06:20AM	3 Stocks Under $15 That Could Make You a Millionaire (InvestorPlace)
Jul-10-24 06:33AM	Vistagen secures new patents for PH80 migraine treatment (Pharmaceutical Technology)
Jul-09-24 08:30AM	Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine (Business Wire) +5.90%
Jun-27-24 08:30AM	Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year (Business Wire) +7.08%
Jun-12-24 08:52AM	VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:02AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript (Insider Monkey)
Jun-11-24 04:20PM	Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (Business Wire)
Jun-07-24 08:30AM	Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 (Business Wire)
May-29-24 08:30AM	Vistagen to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-24 08:30AM	Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference (Business Wire)
May-14-24 06:59AM	3 Must-Have Penny Stocks to Boost Your 2024 Portfolio (InvestorPlace)
May-13-24 10:00AM	Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence (InvestorPlace)
May-07-24 08:30AM	Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference (Business Wire)
Apr-25-24 08:30AM	Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue (Business Wire)
Apr-19-24 07:13AM	7 Stocks Under $15 Predicted to Boom in the Next 2 Years (InvestorPlace)
Apr-09-24 01:28PM	Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027 (InvestorPlace)
08:30AM	Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference (Business Wire)
Apr-01-24 08:30AM	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 (Business Wire)

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

VERA

Vera Therapeutics Inc

VTGN

Vistagen Therapeutics Inc

Upgrade your FINVIZ experience